|
|
Article: Phase III Clinical Trial Of NBI-34060 Initiated In Chronic Insomnia Patients.(Neurocrine Biosciences Inc.)
- Article from:
- Health & Medicine Week
- Article date:
- December 17, 2001
CopyrightCOPYRIGHT 2001 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2001 DEC 17 - (NewsRx.com & NewsRx.net) -- Neurocrine Biosciences, Inc. (NBIX) announced that it has initiated the first pivotal Phase III clinical trial of NBI-34060 in approximately 500 patients with chronic (primary) insomnia.
The Phase III clinical trial is a randomized, double-blind, parallel-group, multicenter study to evaluate the safety of two doses of NBI-34060 Immediate Release (IR) for the long-term treatment of chronic (primary) insomnia in adults. The trial will be conducted in approximately 40 medical sites in the United States and Europe.
"This trial is a major turning point for Neurocrine as we begin our first Phase III program in the ...